摘要
目的研究非致残性缺血性脑血管事件患者的氯吡格雷抵抗情况。方法选取2018年1月—2020年8月于潮州市人民医院就诊的58例非致残性缺血性脑血管事件患者,依据氯吡格雷治疗后情况分为氯吡格雷抵抗组和非氯吡格雷抵抗组,各29例。比较2组治疗7 d后血小板聚集率和miR-26a变化,并分析氯吡格雷抵抗因素。结果氯吡格雷抵抗组血小板聚集率、miR-26a为(43.77±8.46)%、(1.89±0.23)%,高于非抵抗组的(25.02±3.68)%、(0.55±0.12)%,有统计学差异(P<0.05);氯吡格雷抵抗组高血压、糖尿病发病率为44.83%、55.17%,高于非抵抗组的13.79%,20.69%,LDL水平为(4.11±0.53)mmol/L,高于非抵抗组的(3.04±0.41)mmol/L,有统计学差异(P<0.05)。结论氯吡格雷抵抗可降低非致残性缺血性脑血管事件患者血小板抑制效果,临床早期应分析患者相关指标,重点评估合并高血压、糖尿病、吸烟等群体氯吡格雷抵抗风险,以合理制定诊疗计划,保障治疗效果。
Objective To explore the research value of clopidogrel resistance in patients with non disabled ischemic cerebrovascular events.Methods from January 2018 to August 2020,58 patients with non disabling ischemic cerebrovascular events in our hospital were selected and divided into clopidogrel resistance group and non clopidogrel resistance group according to the situation after clopidogrel treatment,with 29 cases in each group.Both groups were treated with clopidogrel.Platelet aggregation rate and miR-26a were compared between the two groups after 7 days of treatment,and clopidogrel resistance factors were analyzed.Results The platelet aggregation rate and miR-26a of clopidogrel resistance group were(43.77+8.46)%and(1.89+0.23)%,higher than those of non resistance group(25.02+3.68)%,(0.55+0.12)%,there was statistical difference(P<0.05);the incidence rate of hypertension and diabetes in clopidogrel resistance group was 44.83%,55.17%,higher than that in non resistance group,and LDL level was(mmol/L),higher than that in group(B 41)mmol/L,the difference was statistically significant(P<0.05).Conclusion Clopidogrel resistance can reduce the effect of platelet inhibition in patients with non disabled ischemic cerebrovascular events.In the early clinical stage,we should analyze the basic indicators and related indicators of patients,and focus on evaluating the risk of clopidogrel resistance in patients with hypertension,diabetes,smoking and other groups,so as to make a reasonable diagnosis and treatment plan and ensure the treatment effect.
作者
曾培灿
陈玉芳
蔡蓉菲
郭文雄
李曼佳
Zeng Peican;Chen Yufang;Cai Rongfei(The People's Hospital of Chaozhlu City,Chaozhou,Guangdong 521000)
出处
《基层医学论坛》
2021年第16期2233-2235,共3页
The Medical Forum
基金
广东省潮州市卫生健康局科研项目(潮卫科研2020008号)。
关键词
非致残性缺血性脑血管事件
氯吡格雷抵抗
抵抗因素
血小板聚集率
Non disabling ischemic cerebrovascular events
Clopidogrel resistance
Resistance factors
Platelet aggregation rate
